Amicus Therapeutics (NASDAQ:FOLD) Upgraded by BidaskClub to Buy

BidaskClub upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a buy rating in a research report report published on Saturday, BidAskClub reports.

A number of other research firms also recently commented on FOLD. ValuEngine upgraded shares of Amicus Therapeutics from a hold rating to a buy rating in a research report on Tuesday, January 7th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a hold rating to a buy rating and set a $9.25 price target on the stock in a research report on Monday, November 4th. HC Wainwright restated a buy rating and set a $20.00 price target on shares of Amicus Therapeutics in a research report on Thursday, January 9th. Cantor Fitzgerald restated an overweight rating on shares of Amicus Therapeutics in a research report on Thursday, October 17th. Finally, Robert W. Baird restated a buy rating and set a $20.00 price target on shares of Amicus Therapeutics in a research report on Thursday, January 9th. Eight investment analysts have rated the stock with a buy rating, Amicus Therapeutics has a consensus rating of Buy and a consensus price target of $18.86.

FOLD stock opened at $9.79 on Friday. Amicus Therapeutics has a 52 week low of $7.11 and a 52 week high of $14.61. The company has a market capitalization of $2.59 billion, a price-to-earnings ratio of -6.23 and a beta of 1.55. The firm’s 50-day moving average is $9.81 and its two-hundred day moving average is $9.94. The company has a current ratio of 6.20, a quick ratio of 6.10 and a debt-to-equity ratio of 0.36.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.08. Amicus Therapeutics had a negative net margin of 216.02% and a negative return on equity of 62.61%. The company had revenue of $48.80 million for the quarter, compared to the consensus estimate of $48.05 million. During the same period in the previous year, the firm earned ($0.84) EPS. Amicus Therapeutics’s revenue was up 136.9% on a year-over-year basis. On average, equities research analysts predict that Amicus Therapeutics will post -1.22 earnings per share for the current year.

In related news, CEO John F. Crowley sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $10.35, for a total value of $1,035,000.00. Following the sale, the chief executive officer now directly owns 1,058,339 shares in the company, valued at approximately $10,953,808.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Margaret G. Mcglynn sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, January 9th. The stock was sold at an average price of $10.00, for a total transaction of $200,000.00. Following the completion of the sale, the director now owns 42,064 shares in the company, valued at $420,640. The disclosure for this sale can be found here. Insiders have sold a total of 323,380 shares of company stock worth $3,228,478 over the last 90 days. 2.50% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FOLD. First Trust Advisors LP bought a new stake in shares of Amicus Therapeutics in the 1st quarter worth approximately $635,000. Wells Fargo & Company MN raised its holdings in shares of Amicus Therapeutics by 3.5% in the 2nd quarter. Wells Fargo & Company MN now owns 252,696 shares of the biopharmaceutical company’s stock worth $3,154,000 after purchasing an additional 8,661 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Amicus Therapeutics in the 2nd quarter worth approximately $3,167,000. Northern Trust Corp raised its holdings in shares of Amicus Therapeutics by 5.4% in the 2nd quarter. Northern Trust Corp now owns 2,659,611 shares of the biopharmaceutical company’s stock worth $33,192,000 after purchasing an additional 136,521 shares in the last quarter. Finally, Profund Advisors LLC raised its holdings in shares of Amicus Therapeutics by 12.5% in the 2nd quarter. Profund Advisors LLC now owns 22,860 shares of the biopharmaceutical company’s stock worth $285,000 after purchasing an additional 2,546 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Featured Article: Average Daily Trade Volume – What You Need to Know

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.